Overcoming standard-of-care resistance in glioblastoma using nanoparticle-based drug delivery targeting the autophagy pathway

Sep 5, 2025Biochemical pharmacology

Using nanoparticles to improve drug delivery and target cell recycling to overcome treatment resistance in glioblastoma

AI simplified

Longevity & Aging on OpenScience ↗PubMed ↗DOI ↗

Abstract

Modulation of autophagy may enhance therapeutic efficacy in treating glioblastoma (GBM).

Glioblastoma is characterized by rapid growth and poor prognosis despite existing treatments.
Autophagy allows tumor cells to survive under various stress conditions, contributing to drug resistance.
Nanoparticle-based drug delivery systems improve drug bioavailability and facilitate targeted delivery to tumor tissues.
Integrating autophagy-targeting strategies with nanoparticle systems could offer a novel approach to overcome resistance.
The dual role of autophagy in GBM progression necessitates careful modulation based on context and timing.

AI simplified

Glioblastoma (GBM) is the most aggressive and lethal primary brain tumor in adults, characterized by rapid growth, diffuse infiltration, and a dismal prognosis. Despite aggressive treatment involving maximal surgical resection followed by radiotherapy and temozolomide (TMZ) chemotherapy, therapeutic outcomes remain poor due to intrinsic and acquired resistance. Autophagy, a catabolic process that degrades damaged cellular components, plays a critical role in this resistance by enabling tumor cells to survive under metabolic, hypoxic, and therapeutic stress conditions. Notably, modulation of autophagy has emerged as a promising avenue to overcome drug resistance. Recent advances in nanomedicine offer innovative strategies to enhance drug delivery and therapeutic efficacy. Nanoparticle-based drug delivery systems (NDDS) improve the bioavailability of drug molecules, facilitate blood-brain barrier (BBB) penetration, and enable targeted delivery to tumor tissues. This review explores the synergistic potential of integrating NDDS with autophagy-targeting strategies to treat GBM. Various nanoparticle platforms-including liposomes, dendrimers, polymeric nanoparticles, and lipid-based carriers-are highlighted for their ability to modulate autophagy and deliver anti-cancer agents effectively. Furthermore, we discuss the dual role of autophagy in GBM progression and the importance of context- and time-specific modulation. Thus, combining autophagy inhibitors or modulators with nanoparticle-based systems and standard therapies holds promise as a novel therapeutic strategy to counteract resistance and improve patient survival in GBM.

Full Text

Full text is available at the source.

View full text (XML) ↗View full text ↗

Overcoming standard-of-care resistance in glioblastoma using nanoparticle-based drug delivery targeting the autophagy pathway

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the longevity & aging brief